BillionToOne logo

BillionToOne

We push the boundaries of molecular diagnostics through quantitative technologies.

815 employees · est. 2016 · Menlo Park, United States

VS
Early is Good logo

Early is Good

Ultra-Sensitive Multi-Omics Biomarker Detection To Transform The Future Healthcare

5 employees · est. 2021 · Indianapolis, United States

BillionToOne is the older company (2016 vs 2021); BillionToOne is the larger of the two.

Side-by-Side Comparison

BillionToOne Early is Good
Founded
2016 older 2021
Headquarters
Menlo Park, United States Indianapolis, United States
Employees
815 larger 5
Industry
Biotechnology, Health Care Health Care
Funding Stage
IPO Seed
Total Funding
$650.63M $5.50M
Funding Rounds
9 2
Services
Development and provision of advanced diagnostic tests, Quantification of disease-causing DNA fragments, Non-invasive prenatal and oncology testing solutions, Monitoring treatment response in cancer patients Not tracked yet
Target Customers
Healthcare Providers, Pregnant Women, Oncologists, Medical Researchers Not tracked yet
Taxonomy
Molecular Diagnostics, Precision Diagnostics, DNA Quantification, Molecular Counting Technology, Disease Detection, Prenatal Testing, Single-gene Disorder Detection, Non-invasive Testing, Blood Test Innovation, Affordable Healthcare Solutions, Patent-pending Technology, Risk Reduction In Diagnostics, Biotechnology Innovation Molecular Diagnostics, Biomarker Detection, Multi-omics, Cancer Detection, DNA Testing, RNA Testing, Protein Testing, Metabolite Testing, Early Disease Detection, Non-invasive Testing, Precision Medicine
Website
billiontoone.com earlyisgood.com
BillionToOne logo

About BillionToOne

BillionToOne, founded in 2016, is a pioneering entity in the Biotechnology and Health Care industries, headquartered in the United States. The company is renowned for its commitment to enhancing the accuracy, efficiency, and accessibility of molecular diagnostics, encapsulated in their slogan: "We p...

Early is Good logo

About Early is Good

Early is Good is a health care startup with a mission to revolutionize the future of healthcare through ultra-sensitive multi-omics biomarker detection. The company's Multi-omic Integration Platform offers a breakthrough approach by combining the detection of DNA, RNA, protein, and metabolite target...

We will tell you when either one moves

BounceWatch watches BillionToOne and Early is Good for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at BillionToOne and Early is Good — by email.

Frequently Asked Questions

BillionToOne — We push the boundaries of molecular diagnostics through quantitative technologies.. Early is Good — Ultra-Sensitive Multi-Omics Biomarker Detection To Transform The Future Healthcare. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
BillionToOne has raised $650.63M while Early is Good has raised $5.50M.
BillionToOne and Early is Good operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare BillionToOne with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at BillionToOne on 9 Jun 2026, and Early is Good on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy